Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

30.71 +0.18 (+0.59%)
Delayed Quote Updated: 2:40 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vera Therapeutics, Inc. - Class A Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate at Upcoming Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years ↗
Vera Therapeutics announces ORIGIN Phase 2b trial data on atacicept, showing sustained IgAN improvement and kidney function stability over 96 weeks. 
Via Benzinga
News headline image
PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug ↗
The company is working on a treatment for IgA nephropathy, a condition that affects how well the kidneys work. 
Via Investor's Business Daily
News headline image
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Vera Therapeutics to Participate at September Investor Conferences
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
VERA Stock Earnings: Vera Therapeutics Misses EPS for Q2 2024 ↗
VERA stock results show that Vera Therapeutics missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Appoints Christy J. Oliger to Board of Directors
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Vera Therapeutics
Via GlobeNewswire
News headline image
Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Vera Therapeutics
Via GlobeNewswire
News headline image
Stericycle, MarineMax, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Wall Street Snaps Five-Week Winning Streak, Economic Growth Slows, Inflation Holds Steady In April: This Week In The Market ↗
U.S. stock market ends 5-week positive streak due to slowing economic momentum, while Nvidia's valuation soars and home prices hit record highs. 
Via Benzinga
Topics Economy
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.